GSK committed up to $750 million to secure global rights to Chimagen Biosciences’ Phase 1-ready tri-specific T-cell engager aimed at multiple myeloma. The deal positions GSK to pursue a higher-order targeting strategy—hitting three immune/tumor targets—contrasting with the more common two-target formats. GSK’s move effectively translates a scientific bet into an execution timeline advantage: the asset is described as Phase 1-ready, with GSK planning development next year. The announcement underscores Big Pharma’s continued appetite for T-cell engager platforms as it seeks new growth beyond existing registries. For Chimagen, the transaction monetizes early-stage platform progress and provides scale-up funding for clinical translation. For the broader sector, the headline is the size of the commitment relative to “Phase 1-ready” stage, reflecting how competition for differentiated immuno-oncology formats is intensifying.